Shinji Matsunaga1, Taro Kishi2, Nakao Iwata3. 1. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, Japan. 2. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. Electronic address: tarok@fujita-hu.ac.jp. 3. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Abstract
OBJECTIVE: To clarify whether memantine is more efficacious in several outcomes and safer than placebo in patients with Lewy body disorders, we performed a meta-analysis of memantine in patients with Lewy body disorders. METHODS: The meta-analysis included randomized controlled trials of memantine for Lewy body disorders in all patients with Lewy body disorders. Motor function, activities of daily living, Neuropsychiatric Inventory, Mini-Mental State Exam, discontinuation rate, and individual side effects were evaluated. RESULTS: No significant effects of memantine on motor function scores, Mini-Mental State Exam scores, Neuropsychiatric Inventory scores, and activity of daily living scores were found. However, memantine was superior to placebo in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change scores (standardized mean difference: -0.26; 95% confidence interval: -0.51 to -0.02; z = 2.08; p = 0.04; two studies; N = 258). Dropout due to all causes, inefficacy, or adverse events were similar in both groups. Moreover, no significant differences in serious adverse events, somnolence/tiredness, stroke, dizziness/vertigo, and confusion were found between the groups. CONCLUSION: Our results suggest that memantine did not have a benefit for the treatment of Lewy body disorders in cognition and motor function. However, memantine may be superior to placebo for the overall impression of the disorders. Further, memantine is well tolerated.
OBJECTIVE: To clarify whether memantine is more efficacious in several outcomes and safer than placebo in patients with Lewy body disorders, we performed a meta-analysis of memantine in patients with Lewy body disorders. METHODS: The meta-analysis included randomized controlled trials of memantine for Lewy body disorders in all patients with Lewy body disorders. Motor function, activities of daily living, Neuropsychiatric Inventory, Mini-Mental State Exam, discontinuation rate, and individual side effects were evaluated. RESULTS: No significant effects of memantine on motor function scores, Mini-Mental State Exam scores, Neuropsychiatric Inventory scores, and activity of daily living scores were found. However, memantine was superior to placebo in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change scores (standardized mean difference: -0.26; 95% confidence interval: -0.51 to -0.02; z = 2.08; p = 0.04; two studies; N = 258). Dropout due to all causes, inefficacy, or adverse events were similar in both groups. Moreover, no significant differences in serious adverse events, somnolence/tiredness, stroke, dizziness/vertigo, and confusion were found between the groups. CONCLUSION: Our results suggest that memantine did not have a benefit for the treatment of Lewy body disorders in cognition and motor function. However, memantine may be superior to placebo for the overall impression of the disorders. Further, memantine is well tolerated.
Authors: Ruth A Cromarty; Greg J Elder; Sara Graziadio; Mark Baker; Laura Bonanni; Marco Onofrj; John T O'Brien; John-Paul Taylor Journal: Clin Neurophysiol Date: 2015-06-27 Impact factor: 3.708
Authors: Laura Brennan; Alexander Pantelyat; John E Duda; James F Morley; Daniel Weintraub; Jayne R Wilkinson; Paul J Moberg Journal: Mov Disord Clin Pract Date: 2015-12-07